

ISSN 3009-3848
ISSNe 3009-383X

Oncology Insights

Official Journal of the Serbian Association for Cancer Research



ISSN 3009-3848
ISSNe 3009-383X

ONCOLOGY INSIGHTS

Official Journal of
the Serbian Association for Cancer Research

Belgrade, Serbia
October, 2023

ONCOLOGY INSIGHTS

Official Journal of the Serbian Association for Cancer Research
Publishing annually

Publisher

Serbian Association for Cancer Research
Belgrade, Serbia

Editor-in-Chief

Dr Milena Čavić

Associate Editors

Dr Milica Pešić, Dr Ivana Z. Matić

Managing Editor

Dr Ana Damjanović Veličković

Technical Editors

Dr Marija Đorđić Crnogorac, Dr Milica Nedeljković

Editors

Dr Radmila Janković, Dr Marko Radulović, Prof. Katarina Zeljić, Dr Ana Krivokuća, Prof. Chiara Ambrogio, Dr Thomas Mohr, Prof. Engin Ulukaya, Prof. Vilma Petrikaite, Prof. Konstantinos Dimas, Dr Cristina Xavier, Dr Remond Fijneman, Prof. Ieronymos Zoidakis, Dr Sergi Castellvi-Bel, Dr Petar Ozretic, Prof. Sonja Levanat

Editorial Council

Dr Ana Đurić, Dr Marko Radulović, Dr Radmila Janković, Prof. Katarina Zeljić, Dr Lidija Todorović

Lector/Corrector

Jana Stefanović

Editorial Office

Serbian Association for Cancer Research

Printed by:

Connect Online Studio
Ćirila i Metodija 2a
Belgrade, Serbia

CIP - Каталогизacija y publikaciji
Narodna biblioteka Srbije, Beograd

616-006-08

ONCOLOGY Insights : official Journal of the Serbian
Associaton for Cancer Research / editor in chief Milena Čavić. -
[Štampano izd.]. - 2023, no. 1- . - Belgrade : Serbian Associaton
for Cancer Research, 2023- (Belgrade : Connect Online Studio). - 30 cm

Godišnje. - Drugo izdanje na drugom medijumu:

Oncology Insights (Online) = ISSN 3009-383X

ISSN 3009-3848 = Oncology Insights (Štampano izd.)

COBISS.SR-ID 125366281

CONTENTS

ONCOLOGY INSIGHTS INFO	I
SDIR6 CONGRESS INFO	III
LEGACY INSIGHTS	1
The foundation of the Serbian Association for Cancer Research	2
SDIR evolution: important steps from 2016 to 2022.	5
FUTURE HORIZONS IN CANCER	7
The importance of sex as a biological variable in cancer research.	8
The Role of Microbiota in Cancer Patients	16
PROCEEDINGS BOOK	23
PLENARY LECTURES	25
Unconventional approaches to the treatment of cancer	25
Targeting KRAS: achievements and drawbacks	25
INVITED LECTURES	26
Discovery of novel HDAC inhibitors for therapy of triple-negative breast cancer – preclinical study	26
Estrogen Receptor Beta promoter methylation as a possible biomarker in breast cancer	26
A new approach to the design of metal-based antineoplastic drugs.	27
Approaches to targeting cancer cell resistances in preclinical research	28
Small hydrophobic molecules in multi-targeted cancer therapy: disruption of plasma membrane and mitochondrial functions	30
Good cop-bad cop: different roles of hsa-miR-93-5p in colorectal cancer	31
Network based approaches in cancer research- chances and challenges	34
Tackling omics research in pathology in a low-budget setting	34
Sex as a biological variable in preclinical melanoma research	35
The importance of adequate molecular diagnostics in the era of precision oncology – focus on lung cancer	36
High-throughput screening of multidrug-resistance markers in non-small cell lung carcinoma patient-derived cells – contribution to personalized treatment.	37
Circulating cytokines as potential biomarkers of disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy	40
Targeting chitinase 3-like 1 for the treatment of pancreatic cancer	42
Establishment of a first cancer Biobank at the Institute for Oncology and Radiology of Serbia – advantages, challenges and future perspectives	44
Advancing reversible immunocapture toward scalable purification of extracellular vesicles	45
Dying of cancer cells feeds the others to create more aggressive tumor	46
The role of Hedgehog signaling pathway in plasticity, stemness and resistance of melanoma.	47

What is new in care of Adolescents and Young Adults, AYA with cancer.	49
Control of IFN- γ Responsiveness and Metastatic Potential in Melanoma by GSTA4	50
MicroRNAs – biomarker properties in prostate cancer.	52
Significance of molecular diagnostics in therapy of chronic lymphocytic leukemia.	54
ORAL PRESENTATIONS.	57
The PDK-1 inhibitor GSK2334470 induces cell death and G1 cell cycle arrest in human pancreatic cancer cells	57
Suppressor Effects of The Mixed Ligand Platinum (II) Saccharinate Complexes (<i>trans</i> -[Pt(sac) ₂ (PPh ₃) ₂] and <i>trans</i> -[Pt(sac) ₂ (PPh ₂ Cy) ₂]) on <i>In Vitro</i> And <i>In Vivo</i> Angiogenesis	57
All-trans retinoic acid activities in Merkel cell carcinoma: implication of the retinoic gene signature	58
Predicting response to chemoradiotherapy in locally advanced rectal cancer using MRI-based radiomics features	59
Transcriptomic profiling of the early stage squamous cell lung cancer	59
The role of p53 family in melanoma development and therapy resistance	60
The anticancer effects of triterpene saponin deglucocyclamine isolated from <i>Cyclamen hederifolium</i>	61
The effect of diiron thiocarbonyl complex on tumor cells of different grade.	61
The effects of cisplatin-ibuprofen conjugate free and immobilized in mesoporous nanostructured silica on the change of morphology of mouse melanoma cells, and antitumor potential <i>in vivo</i>	62
Role of Claudins 3, 4 and 7 in Triple Negative Breast Cancer progression.	63
Impairment of cystatin F activation can increase the cytotoxicity of NK cells.	63
Cisplatin-Killed Cells as a Preferable Method for Generating Tumor Cell-Based Vaccines.	64
Modes of Activity and Prognostic Significance of the Hedgehog-Gli Signaling Pathway in Prostate Cancer.	64
Platelet-released factors boost proliferation of multiple myeloma cells and changes in bone marrow stroma with implications of NF κ B pathway involvement	65
<i>In vitro</i> anticancer activity of kaempferol-derived flavonoids against pancreatic adenocarcinoma.	66
Amassing a treasure trove for drug repurposing using chemoproteomics.	66
Characterization of heterogeneity of cancer-associated fibroblasts isolated from PDAC patients	67
Exploring the anticancer activity of essential oil of <i>Satureja montana L.</i> from Montenegro	67
POSTER PRESENTATIONS.	69
A pilot study of the association between variants rs25487 of <i>XRCC1</i> gene, rs1801320 of <i>RAD51</i> gene, and rs13181 of <i>ERCC2</i> gene and acute toxicity of radiation therapy after radical prostatectomy in patients with prostate cancer	69
Overview and data management of gastropancreatic oncology biobank sample and data collection.	69
Detection of resistant <i>EGFR</i> T790M mutation from liquid biopsy samples of patients with advanced non-small cell lung cancer: comparison of qPCR and dPCR detection methods.	71
Histomics: Bridging Radiomics and Histopathology Towards Advancing Prognostication of Breast Cancer Metastasis	71
Effects of promoter methylation and mutation on <i>BRCA1/2</i> expression in ovarian cancer.	74
Ultra-short cfDNA fragment detection during systemic therapy of advanced-stage colorectal cancer	75

Comparison of variant calling tools for mutation analysis of <i>BRCA1</i> and <i>BRCA2</i> genes in patients with epithelial ovarian cancer	76
Expression and heteromerization of adenosine A2A and dopamine D2 G protein-coupled receptors in neuroendocrine tumors of the lung	76
Detection of viral proteins in locally advanced rectal cancer patient samples by mass spectrometry – predictive potential for response to neoadjuvant chemoradiotherapy.	77
Prognostic Value of Combined Hematological/Biochemical Indexes and Tumor Clinicopathologic Features in Colorectal Cancer Patients—A Pilot Single Center Study	78
The Polymorphisms of Genes Encoding Antioxidant Enzymes Modulate the Risk for Testicular Germ Cell Tumor.	79
Complementarity of miR-203a-3p and ETS-1 sequences may influence aggressiveness of papillary thyroid carcinoma.	79
Characterization of nischarin expression in pancreatic ductal adenocarcinoma	80
Expression profile of CD81 gene transcripts in colorectal cancer	81
Genetic polymorphisms of enzymes involved in redox homeostasis can influence survival in smokers and overweight patients with prostate cancer	81
Expression of long non-coding RNA HOTAIR in rectal cancer as a potential predictor of response to chemoradiotherapy	82
Prognostic potential of redox status, SLFN11, and PD-L1 in colorectal cancer patients	82
Interleukin-6, a potential plasma biomarker for diagnosis and prognosis of thyroid neoplasms	83
The effect of tyrosine kinase inhibitors in high-grade glioma patient-derived cells	84
The significance of interleukin-8 in hormonally dependent early breast cancer – association with the established parameters ER/PR and HER2	84
Variant rs745430558 in the <i>SMAD4</i> gene promoter as a biomarker for adenocarcinoma of the pancreas	85
Effect of BET inhibitors on cancer stem cells sorted from primary oral cancer cell culture.	85
Precision medicine in gastrointestinal oncology – gemcitabine-based systemic chemotherapy in patients with advanced/metastatic pancreatic carcinoma	86
Precision medicine in gastrointestinal oncology – therapeutic approach in patients with braf mutant metastatic colorectal cancer: a retrospective analysis.	86
Iron metabolism in the prognosis of epithelial ovarian cancer	87
Can serum HER2 testing add prognostic value to routine tissue HER2 analysis for primary breast cancer patients?	87
Prognostic significance of the localization of the primary tumor and HER2-receptor expression in KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy	88
Expression Profile of Sex Hormone Receptors in Head and Neck Cancer: Unraveling Gender Disparities.	88
Circulating cytokine changes in BRAFwt MM patients during anti-PD-1 therapy.	89
Prognostic significance of pathologically detected extramural venous invasion (EMVI) in rectal carcinoma	90
Genomic instability as a prognostic marker in malignant brain cancer	90
Head and neck cancer: single- and two-stage reconstruction	91
Simultaneous <i>EGFR</i> L858R and T790M mutations in treatment-naïve metastatic lung adenocarcinoma: a case study and therapeutic implications	91

Tracing the connection between trace metals and oxidative stress in malignant brain tumors and hydrocephalus . . .	92
Anti-cancer activity of newly synthesized derivatives of nicotinic acid on several monolayer and three-dimensional solid tumor models	92
The effect of <i>Lactobacillus salivarius</i> on AKT-mTOR signaling pathway in normal, dysplastic, and oral cancer cell co-cultures	93
Violacein enhances the cytotoxic effect of commonly used chemotherapeutics on rhabdomyosarcoma cells	94
Anticancer effects of non-toxic repurposed drugs on hamster fibrosarcoma – fast applicable in oncology	94
Potential of Tamoxifen-based Copper(II) Dichloride in Breast Cancer Therapy	95
The mechanism of action of ruthenium compounds on ovarian tumor cells OVCAR-3.	95
Multidrug resistant non-small cell lung cancer cells present collateral sensitivity to platinum-based drugs.	98
Anoikis as a novel mode of shikonin derivatives anticancer action on C6 glioma cells	98
Different mitochondrial response in A549 KRASG12S cells and MCF7 KRAS wild type cells to the treatment with mitochondrial superoxide radicals triggering agent 2-(1-Benzyl-4-piperidinylamino)-4-(4-chlorophenyl)-4-oxo-N-phenylbutyramide (BPCPh)	99
Anticancer activity of diphenyltin(IV) compounds bearing carboxylato N-functionalized 2-quinolones	100
Bismuth ferrite nanoparticles increase ROS production and p62 expression in A375 melanoma and HeLa cells.	100
Stimulation and inhibition of NF- κ B by repurposed drugs – effects on hamster fibrosarcoma.	101
Targeting Tumor pH: The Role of Sodium Bicarbonate in Cancer Treatment	101
Antitumor potential and impact on redox homeostasis of the essential oil of Black pepper (<i>Piper nigrum L.</i>)	102
Antiparasitic drug Ivermectin, a potential anticancer drug.	103
Role of the SALL2 Transcription Factor in Epithelial-Mesenchymal Transition and its Implication in Tumor Malignancy in Colorectal Cancer	103
Cytotoxic activity of extract of <i>Helichrysum plicatum</i> DC. on human cancer cells <i>in vitro</i>	104
The role of ROS in MAPK-dependent autophagy involved in phorbol myristate acetate-induced macrophage differentiation of HL-60 leukemia cells	104
Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome	105
Benefit of immunotherapy administration on overall survival of patients with NSCLC according to real world data analysis	106
INDEX	107

ONCOLOGY INSIGHTS

Aims and Scope

Oncology Insights is a yearly oncological open-access peer-reviewed journal that publishes new research from different areas of oncology. It strives to provide a platform for the exchange of cutting-edge research and knowledge in the field of oncology. This journal aims to advance the understanding, prevention, diagnosis and treatment through the dissemination of high-quality scientific discoveries.

The journal applies a fair and accurate peer review process, employing double-blind review methodologies. Acceptance of manuscripts is based on their scientific merit, originality, clarity, and contribution to the field.

Topics

Oncology Insights covers a wide spectrum of topics within the field of oncology, including but not limited to:

- Basic and Translational Research
- Clinical Oncology
- Radiation Oncology
- Surgical Oncology
- Pediatric Oncology
- Hematologic Oncology
- Palliative Care
- Epidemiology and Public Health
- Cancer Genetics
- Immunotherapy and Targeted Therapies
- Experimental Therapeutics
- Computational Biology and Artificial Intelligence

About/Information

Oncology Insights welcomes various types of contributions including original research articles, review articles, case reports, case studies, clinical trials, registered reports, comments, brief communications, editorials, letters to the editor, perspectives, and conference papers from a wide range of disciplines related to cancer research.

Through encouraging interdisciplinary collaborations, the journal welcomes contributions that integrate oncology with related fields such as immunology, genetics, biochemistry, radiology, and other relevant disciplines. The journal places a special emphasis on publishing research that highlights emerging trends, novel technologies, and innovative approaches in cancer research and clinical practice.

Oncology Insights is intended for a diverse readership, including oncologists, researchers, clinicians, nurses, allied healthcare professionals, patients, patient advocates, policymakers, and all stakeholders involved in the prevention, diagnosis, and treatment of cancer. It adopts a global perspective, encompassing research from diverse regions addressing oncological challenges that may vary across different populations.

The journal is committed to upholding the highest ethical standards in research and publication provided by established international guidelines.

Periodically, Oncology Insights may publish special issues focusing on specific topics to highlight particular areas of interest or emerging needs.

Authors are provided with clear and comprehensive guidelines for manuscript preparation, including structure, formatting, and other specific requirements.

Esteemed colleagues,

It is a rare honor and privilege in a scientist's career to shape joint efforts and dedication of a group of scientific enthusiasts into a tangible outcome - ***Oncology Insights, the Official Journal of the Serbian Association for Cancer Research*** (srp. Srpsko društvo istraživača raka, SDIR).

The first volume of Oncology Insights has been derived from years of scientific contributions of many individuals and institutions who have selflessly devoted their expertise, ideas and time to establish the SDIR society that today resonates with integrity and charm. In the future, we will strive to maintain those standards, always aiming higher. Thus, we encourage researchers, physicians, nurses, laboratory technicians, as well as patients, survivors, caregivers, and patient advocates to offer their valuable expert insights that will stimulate future progress of oncology in Serbia and worldwide.

Over the last 20 years, we have witnessed remarkable progress in the field of cancer research. Oncology Insights aims to play an integral role in supporting that progress by providing a platform for sharing cutting-edge research, creating a space for new collaborations, partnering established researchers with young investigators, and serving as a home for oncology professionals of various specialties dedicating their careers to this challenging research field.

Oncology Insights pledges to evolve, adapt, reinvent, redefine, and reshape its content to serve its members and inevitable advances in the field. We hope you will be a part of its success story by providing evidence-based, unbiased multidisciplinary content, feeling both an honor and a duty to treat cancer research with the same care, passion, and dedication which individuals with cancer deserve and expect.

Please tune all your senses to enjoy the intellectual feast spread through the pages of this inaugural journal volume. The future of Oncology Insights will be shaped by you.

With kind regards,



Milena Čavić, SDIR President
Editor-in-Chief
Oncology Insights
Official Journal of the Serbian Association for Cancer Research






The first number of Oncology Insights includes
PROCEEDINGS BOOK of
THE SIXTH CONGRESS OF THE SERBIAN ASSOCIATION FOR CANCER RESEARCH
with international participation



From Collaboration to Innovation in Cancer Research

2nd – 4th October 2023
Royal Inn Hotel, Belgrade

SDIR-6 ORGANIZER
Srpsko društvo istraživača raka (SDIR)
Serbian Association for Cancer Research (SACR)
www.sdir.ac.rs



Dear colleagues,

We are very pleased to welcome you to the 6th Congress of the Serbian Association for Cancer Research (SDIR) with international participation "From Collaboration to Innovation in Cancer Research" which will be held on October 2-4 2023, at the Royal Inn Hotel, Kralja Petra 56, Belgrade, Serbia.

During the three-day congress, lectures will be given by distinguished Serbian and international researchers, covering the following topics:

- Tumour metabolism and biology
- Epigenetics and gene regulation in cancer
- Bioinformatics and artificial intelligence in cancer research
- Omics approaches in cancer research
- Therapy response and resistance
- Clinical and translational oncology
- Immunooncology
- New and challenging drug targets
- Pathways to innovation in cancer research

We are pleased to announce that our sixth congress is actively supported by the European Association for Cancer Research (EACR). National and regional cooperation is also important, and so representatives from our friend societies will be attending our congress.

The timing of the organisation of SDIR-6 is important for the establishment of our national society's journal *Oncology Insights*. The abstracts of the sixth congress will be published in the very first issue of the journal.

Advances and innovations in cancer research are based on growing scientific knowledge and collaboration. We believe you will enjoy the lively atmosphere of the congress and that fruitful scientific discussions will help you build new collaborations and develop new ideas.


We look forward to welcoming you in Belgrade!

Kind regards,

on behalf of the SDIR-6 Organizing Committee



Prof. dr Katarina Zeljić
Faculty of Biology, University of Belgrade
President of the SDIR-6 Organizing Committee



SDIR-6 ORGANIZING COMMITTEE

President: Prof. dr Katarina Zeljić, Faculty of Biology, University of Belgrade

Dr Milena Čavić, Institute for Oncology and Radiology of Serbia

Dr Milica Pešić, Institute for Biological Research "Siniša Stanković", University of Belgrade

Dr Radmila Janković, Institute for Oncology and Radiology of Serbia

Dr Marko Radulović, Institute for Oncology and Radiology of Serbia

Prof. dr Katarina Zeljić, Faculty of Biology, University of Belgrade

Dr Ivana Matić, Institute for Oncology and Radiology of Serbia

Dr Ana Krivokuća, Institute for Oncology and Radiology of Serbia

Dr Lidija Todorović, The Vinča Institute of Nuclear Sciences, University of Belgrade

Dr Jelena Spasić, Institute for Oncology and Radiology of Serbia

Dr Nina Petrović, The Vinča Institute of Nuclear Sciences, University of Belgrade

Dr Milica Nedeljković, Institute for Oncology and Radiology of Serbia

Dr Sofija Jovanović Stojanov, Institute for Biological Research "Siniša Stanković", University of Belgrade

Dr Ana Damjanović Veličković, Institute for Oncology and Radiology of Serbia

Dr Marija Đorđić Crnogorac, Institute for Oncology and Radiology of Serbia

Dr Jelena Grahovac, Institute for Oncology and Radiology of Serbia

Dr Ana Đurić, Institute for Oncology and Radiology of Serbia

Dr Tijana Išić Denčić, Institute for the Application of Nuclear Energy - INEP

Dr Bojana Kožik, The Vinča Institute of Nuclear Sciences, University of Belgrade

Ivana Pašić, Institute for Oncology and Radiology of Serbia

Aleksandra Stanojević, Institute for Oncology and Radiology of Serbia

Mladen Marinković, Institute for Oncology and Radiology of Serbia

Valentina Karadžić, Institute for Oncology and Radiology of Serbia

Marina Popović Krneta, Institute for Oncology and Radiology of Serbia

Ana Stepanović, Institute for Biological Research "Siniša Stanković", University of Belgrade

SDIR-6 SCIENTIFIC COMMITTEE

President: Dr Milena Čavić, Institute for Oncology and Radiology of Serbia

Dr Milena Čavić, Institute for Oncology and Radiology of Serbia

Dr Milica Pešić, Institute for Biological Research "Siniša Stanković", University of Belgrade

Dr Radmila Janković, Institute for Oncology and Radiology of Serbia

Dr Marko Radulović, Institute for Oncology and Radiology of Serbia

Prof. dr Katarina Zeljić, Faculty of Biology, University of Belgrade

Dr Ivana Matić, Institute for Oncology and Radiology of Serbia

Dr Ana Krivokuća, Institute for Oncology and Radiology of Serbia

Prof. dr Tatjana Simić, Faculty of Medicine, University of Belgrade

Dr Ljubica Harhaji-Trajković, Institute for Biological Research "Siniša Stanković", University of Belgrade

Dr Miljana Tanić, Institute for Oncology and Radiology of Serbia

Dr Lidija Todorović, The Vinča Institute of Nuclear Sciences, University of Belgrade

Dr Jelena Spasić, Institute for Oncology and Radiology of Serbia

Dr Nina Petrović, The Vinča Institute of Nuclear Sciences, University of Belgrade

Dr Nevenka Gligorijević, Institute for Oncology and Radiology of Serbia

Dr Ana Podolski-Renić, Institute for Biological Research "Siniša Stanković", University of Belgrade

Dr Jelena Dinić, Institute for Biological Research "Siniša Stanković", University of Belgrade

Prof. Chiara Ambrogio, Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino

Dr Thomas Mohr, Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna

Prof. Engin Ulukaya, Medical Faculty of Istinye University

Prof. Vilma Petrikaite, Life Sciences Center, Vilnius University

Prof. Konstantinos Dimas, Faculty of Medicine - University of Thessaly

Dr. Cristina Xavier, i3S - Institute for Research and Innovation in Health, Porto

Dr Remond Fijneman, the Netherlands Cancer Institute

Dr Ieronymos Zoidakis, Biomedical Research Foundation Academy of Athens, Greece

Dr Sergi Castellvi-Bel, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona

Dr Petar Ozretić, Ruđer Bošković Institute, Zagreb

Prof. Sonja Levanat, Ruđer Bošković Institute, Zagreb

P19**The effect of tyrosine kinase inhibitors in high-grade glioma patient-derived cells**

Emma Lupšić¹, Jelena Dinić¹, Igor Nikolić^{2,3}, Sofija Jovanović Stojanov¹, Milica Pešić¹ and Ana Podolski-Renić¹

¹Institute for Biological Research "Siniša Stanković" – National Institute of the Republic of Serbia, University of Belgrade, Despota Stefana 142, 11060 Belgrade, Serbia

²Clinic for Neurosurgery, Clinical Center of Serbia, Pasterova 2, 11000 Belgrade, Serbia

³School of Medicine, University of Belgrade, Doktora Subotića 8, 11000 Belgrade, Serbia

Background: High-grade gliomas are the most frequently diagnosed malignant brain tumors in adults, with a very unfavorable prognosis. Although various strategies have been applied in the clinical setting, no significant progress has been made in the treatment of high-grade glioma. Clinical trials continue to expand into new approaches such as targeted agents and immunotherapy. Here, we performed pharmacological screening of tyrosine kinase inhibitors (TKIs) on patient-derived glioma cells *ex vivo* and assessed the expression of multidrug resistance (MDR) marker in glioma and stromal (non-glioma) cells. The effects of TKIs have been compared with chemotherapeutic agents approved for the treatment of high-grade glioma. **Material and Methods:** Primary patient-derived cell cultures were established from resections of high-grade gliomas. After short-term culturing (2-3 weeks), a mixed population of glioma and non-glioma cells was treated with 4 TKIs (alectinib, dabrafenib, trametinib, and nintedanib), as well as temozolomide (TMZ) and carmustine (BCNU). The maximum achieved concentration in human plasma during therapy (C_{max}) was set as the upper limit and 4 lower concentrations were also used during the study. An immunofluorescence assay allowing discrimination of glial fibrillary acidic protein antibody-positive glioma cells versus negative non-glioma cells was performed using an ImageXpress Pico high-content imager (Molecular Devices) with CellReporterXpress 2.9 software. The MDR marker (ABCB1) was analyzed with the corresponding antibody in the same immunoassay. **Results:** Among the compounds tested, alectinib and TMZ did not affect cell growth and did not change the number of ABCB1-positive cells. Other compounds significantly inhibited the growth of glioma cells. However, they were not selective towards glioma cells, on the contrary, they showed greater cytotoxicity in non-glioma cells. The number of glioma cells positive for the ABCB1 marker increased significantly after treatment with dabrafenib, nintedanib, and BCNU, while trametinib and did not change ABCB1 expression in glioma cells. Stromal (non-glioma) cells generally followed the pattern of ABCB1 observed in glioma cells. **Conclusions:** Novel functional immunoassay may provide valuable information on the sensitivity of high-grade gliomas to different TKIs and possible treatment outcomes based on the expression of MDR marker. **Keywords:** ABCB1, high-grade glioma, immunoassay, patient-derived cell culture, tyrosine kinase inhibitors

P20**The significance of interleukin-8 in hormonally dependent early breast cancer – association with the established parameters ER/PR and HER2**

Jelena Milovanović¹, Jelena Hranisavljević², Tijana Vujasinović¹, Nataša Todorović-Raković¹

¹Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia

²Laboratory for Radiobiology and Molecular Genetics, Vinča Institute of Nuclear Sciences, Belgrade, Serbia

Background: Interleukin-8 (IL-8) is a multifunctional cytokine linked to cancer progression. Studies have confirmed high IL-8 levels in HER2-enriched and basal-like (ER⁻) primary breast tumors. The aim of this study was to evaluate the relationship between intratumoral IL-8 protein levels and clinical outcome in hormone dependent (ER⁺) primary breast cancer patients. **Patients and methods:** The study included 65 early-stage breast cancer patients with detectable levels of hormone receptors (ER^{>0}, PR^{>0}), all of whom had not received any prior hormonal or chemotherapeutic systemic therapy. The median follow-up was 144 months. Steroid hormone receptor status was determined by ligand-binding assay. HER2 status (absence or presence of gene amplification) was determined by chromogenic *in situ* hybridization (CISH). IL-8 protein levels were determined in cytosol tumor extracts by quantitative ELISA. ER level of 10 fmol/mg, PR level of 20 fmol/mg and the median IL-8 concentration level of 88.8 pg/mg, were used as cut-off values. **Results:** There was a significant difference in relapse free survival (RFS) between IL8^{low} and IL8^{high} subgroups of patients (Log rank test, p=0.002). Considering subgroups of patients stratified in different phenotypes according to receptor status and the median IL-8 value, if IL-8 is highly expressed, the influence of ER is weaker and there was no significant difference in RFS between subgroups with ER^{low}IL8^{high} and ER^{high}IL8^{high} phenotypes. The same is true for PR and HER2 and there was no significant difference in RFS between subgroups with PR^{low}IL8^{high} and PR^{high}IL8^{high} phenotypes, neither between subgroups with HER2⁻IL8^{high} and HER2⁺IL8^{high} phenotypes. On the other hand, subgroup with ER^{high}IL8^{low}

phenotype had significantly longer RFS compared to those with ER^{low}IL8^{high} and ER^{high}IL8^{high} phenotypes ($p=0.02$, $p=0.04$, respectively); subgroup with PR^{low}IL8^{low} phenotype had significantly longer RFS compared to those with PR^{low}IL8^{high} and PR^{high}IL8^{high} phenotypes ($p=0.003$, $p=0.02$, respectively); and subgroup with HER2–IL8^{low} phenotype had significantly longer RFS compared to those with HER2–IL8^{high} and HER2+IL8^{high} phenotypes ($p=0.01$, $p=0.02$, respectively). **Conclusions:** IL-8 is a potential biomarker of unfavorable prognosis in hormone dependent breast cancer that is associated with the established parameters ER/PR and HER2. Receptor-mediated signaling could act additively with IL-8 signaling in progression of hormone dependent breast cancer.

Keywords: biomarker, breast cancer, HER2, hormone receptor, interleukin-8.

P21

Variant rs745430558 in the *SMAD4* gene promoter as a biomarker for adenocarcinoma of the pancreas

Jelena Liubičić¹, Aleksandar Bogdanović^{2,3}, Tamara Babić¹, Jovana Despotović¹, Vladimir Dugalić^{2,3}, Aleksandra Nikolić¹

¹ Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia

² Clinic for Digestive Surgery, University Clinical Center of Serbia, Belgrade, Serbia

³ Faculty of Medicine, University of Belgrade, Serbia

Background: Our previous study has identified variant rs745430558 in the *SMAD4* gene promoter as potential biomarker for adenocarcinoma of the pancreas. The allele delTT (10T instead of 12T) was present in malignant pancreatic tissue with a prevalence of 88%. As analysis of cfDNA in liquid biopsy represents a noninvasive approach for the diagnosis and monitoring of malignancies, the aim of this study was to determine the presence of 12T and 10T alleles in the peripheral blood of patients with suspected pancreatic malignancy. **Material and Methods:** The study was performed using cell-free DNA (cfDNA) isolated from the serum of 15 patients with morphological alterations of the pancreas. The presence of 12T and 10T alleles was assessed by allele specific quantitative real-time PCR. **Results:** Of 15 analyzed samples, 13 were diagnosed with adenocarcinoma of the pancreas (AcP), 1 with neuroendocrine tumor (NET), and 1 with pancreatitis. The 10T allele was present in 84.7% of cases with AcP and also in the sample from the patient with NET. In patient with pancreatitis only the 12T allele was detected. **Conclusion:** Our research has shown that the results of liquid biopsy of patients with AcP are in agreement with tissue specimens analysis. Targeted detection of the rs745430558 10T variant in patients with suspected pancreatic malignancies could be a potential biomarker for diagnosis of AcP in the future.

Keywords: cfDNA, liquid biopsy, pancreatic cancer

P22

Effect of BET inhibitors on cancer stem cells sorted from primary oral cancer cell culture

Dijana Mitić, Miloš Lazarević, Milica Jakšić Karišik, Jelena Milašin

Department of Human Genetics, School of Dental Medicine, University of Belgrade

Background: Oral cancer is the most common malignant tumor in the oral and maxillofacial region, and squamous cell carcinoma (OSCC) accounts for 80% of tumors of the oral cavity. Despite improvements in OSCC management, survival rates remain relatively low and the discovery of novel anti-neoplastic agents are urgently needed. The study investigated the cytotoxic effect of three BET inhibitors (JQ1, iBET-151, iBET-762), and one antitumor plant alkaloid (paclitaxel) on cancer stem cells (CSCs), sorted from primary oral cancer cell culture. **Material and methods:** Magnetic sorting was used to gain CD44 and CD133 positive cells. Double negative cells served as a control. Cells were seeded in 96 well plates, and 10 μ M dose of drugs were added to the wells. After 24, 72 hours, and 7 days MTT was performed. **Results:** Real-time PCR analysis confirmed adequate sorting of the double positive (CD44+ and CD133+) cells, with negligible to none of the marker's expression in double negative cells. After 24h of treatment no significant cytotoxicity of the drugs was observed, in comparison to untreated cells. On 48h of treatment there was significant reduction of the cells in the presence of the drugs, but no difference was observed between CSCs and control cells. In longer treatment period (7 days), there was significant difference in cell survival between CSCs and control, in presence of the drugs, for JQ1 ($p<0.05$), paclitaxel ($p<0.01$), iBET 151 and iBET 762 ($p<0.001$). **Conclusions:** The investigated drugs were relative efficient in treatment of tumor cells, but CSCs remain more resistant to the therapy in comparison to the control. New investigations should be aimed at the successful reduction of CSCs.

Keywords: cancer stem cells, iBET, magnetic sorting, oral cancer cell line, qPCR